#USA #ALS #Worcester #Leal Therapeutics #LTX-001

Leal Therapeutics Secures $30 Million in Series A Financing

Leal Therapeutics, a biopharmaceutical company focused on neuro-metabolic therapeutics, announced on August 17, 2026, that it has successfully raised an additional $30 million in its Series A financing round. The funding, which includes contributions from new investor Eli Lilly and Company along with existing backers, is aimed at propelling the company's clinical projects involving its treatment candidates, LTX-001 and LTX-002.

The latest funding will significantly boost the progress of LTX-001, an innovative oral treatment designed for adults experiencing schizophrenia. With this financial influx, Leal Therapeutics can now advance LTX-001 through to an initial readout from its Phase 1b/2a clinical trial, which has just begun recruitment. Preliminary data is expected by the end of the current year.

LTX-001 has undergone initial assessments, including single ascending dose and multiple ascending dose trials, showing a promising safety profile and physiological activity within the central nervous system (CNS). These results bolster the company’s confidence as it enters the pivotal phases of clinical testing.

In addition to advancing research on LTX-001, the funds will also facilitate ongoing clinical evaluation of LTX-002 for amyotrophic lateral sclerosis (ALS). LTX-002 is designed to complement existing treatments by restoring healthy sphingolipid levels in the CNS, and is currently being investigated in a broader Phase 1/2 clinical trial.

Dr. Asa Abeliovich, the founder and CEO of Leal Theraeutics, expressed enthusiasm about the new partnership with Lilly. He remarked on the critical nature of the funding, primarily as it aligns with upcoming clinical milestones for both LTX-001 and LTX-002. Dr. Abeliovich highlighted the significance of the investment to further their mission in targeting high-need CNS disorders, particularly focusing on schizophrenia and ALS.

Leal Therapeutics, which operates out of Worcester, Massachusetts, focuses its research on developing therapies that address critical intersections within CNS and metabolic disorders. Since its inception in 2021, it has been dedicated to leveraging advanced genetic, genomic, and biomarker analyses in therapeutic development. The company aims not only to create innovative drug products but is also developing a next-generation delivery platform to enhance therapeutic access to the brain via novel transport mechanisms.

The funding corresponds with increasing investment interest in mental health therapeutics, underscoring the urgent need for effective treatments for schizophrenia. Given the ongoing challenges within psychiatric care and the limited availability of efficacious options, LTX-001’s progression through the clinical pipeline could represent a significant advancement in treatment modalities available to clinicians.

In closing, Leal Therapeutics stands at a pivotal juncture in its development path. With robust support from its investors, the company is set to make strides in both schizophrenia and ALS management, potentially transforming the landscape for individuals struggling with these debilitating conditions. As developments unfold, the medical community and patients alike will be eager to witness the outcomes of these promising therapeutic candidates.